Hosted on MSN1mon
BIAL’s first subject completes full dose regimen in Parkinson’s treatment trialBIAL has reported the completion of the full dose regimen for the first subject in the multicentre Phase II ACTIVATE trial of the allosteric activator of beta-glucocerebrosidase (GCase), BIA 28 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback